Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
17 Januar 2024 - 10:30PM
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines, today
announced that, effective on January 16, 2024, the company granted
stock options to purchase an aggregate of 13,300 shares of common
stock to 2 new employees, as a material inducement to their
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted have an exercise price of
$4.99 per share, which is equal to the closing price of Stoke’s
common stock on January 16, 2024. Each option will vest over a
4-year period, with 1/4th of the shares underlying the employee’s
option vesting on the one-year anniversary of the applicable
vesting commencement date and the remaining shares thereafter
vesting monthly at a rate of 1/48th of the shares underlying each
employee’s option over the following 36 months, subject to the
employee’s continued employment with Stoke on such vesting dates.
The options have a term of 10 years and are subject to the terms
and conditions of the 2023 Inducement Plan and the stock option
agreement covering the grant.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines. Using
Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene
Output) approach, Stoke is developing antisense oligonucleotides
(ASOs) to selectively restore protein levels. Stoke’s first
compound, STK-001, is in clinical testing for the treatment of
Dravet syndrome, a severe and progressive genetic epilepsy. Dravet
syndrome is one of many diseases caused by a haploinsufficiency, in
which a loss of ~50% of normal protein levels leads to disease.
Stoke is pursuing the development of STK-002 for the treatment of
autosomal dominant optic atrophy (ADOA), the most common inherited
optic nerve disorder. Stoke’s initial focus is haploinsufficiencies
and diseases of the central nervous system and the eye, although
proof of concept has been demonstrated in other organs, tissues,
and systems, supporting its belief in the broad potential for its
proprietary approach. Stoke is headquartered in Bedford,
Massachusetts with offices in Cambridge, Massachusetts. For more
information, visit https://www.stoketherapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117695537/en/
Stoke Media & Investor Contacts: Dawn Kalmar Chief
Communications Officer dkalmar@stoketherapeutics.com
781-303-8302
Eric Rojas Vice President, Investor Relations
IR@stoketherapeutics.com 617-312-2754
Stoke Therapeutics (NASDAQ:STOK)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Stoke Therapeutics (NASDAQ:STOK)
Historical Stock Chart
Von Nov 2023 bis Nov 2024